EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY

被引：0

作者：

Wedemeyer, Heiner ^{[1
]}

Aleman, Soo ^{[2
]}

Brunetto, Maurizia ^{[3
]}

Blank, Antje ^{[4
]}

Andreone, Pietro ^{[5
]}

Bogomolov, Pavel ^{[6
]}

Chulanov, Vladimir ^{[7
]}

Mamonova, Nina ^{[7
]}

Geyvandova, Natalia ^{[8
]}

Morozov, Viacheslav ^{[9
]}

Sagalova, Olga ^{[10
]}

Stepanova, Tatyana ^{[11
]}

Manuilov, Dmitry ^{[12
]}

Mercier, Renee-Claude ^{[12
]}

An, Qi ^{[12
]}

Flaherty, John ^{[12
]}

Osinusi, Anu ^{[12
]}

Lau, Audrey ^{[12
]}

zur Wiesch, Julian Schulze ^{[13
]}

Cornberg, Markus ^{[1
]}

Zeuzem, Stefan ^{[14
]}

Lampertico, Pietro ^{[15
,16
]}

机构：

[1] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany

[2] Karolinska Inst, Dept Infect Dis, Karolinska Univ Hosp, Stockholm, Sweden

[3] Univ Pisa, Univ Hosp Pisa, Dept Clin & Expt Med, Hepatol Unit,Reference Ctr Tuscany Reg Chron Live, Pisa, Italy

[4] Heidelberg Univ Hosp, Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany

[5] Univ Modena & Reggio Emilia, Baggiovara Hosp, Internal Med, Reggio Emilia, Italy

[6] Moscow Reg Res Clin Inst, State Budgetary Inst Hlth Care Moscow Reg, Moscow, Russia

[7] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect D, Moscow, Russia

[8] Stavropol Reg Hosp, Stavropol, Russia

[9] LLC Med Co Hepatolog, Samara, Russia

[10] Southern Ural State Madical Univ, Minist Hlth Russian Federat, Fed State Funded Inst Higher Educ, Chelyabinsk, Russia

[11] Ltd Liabil Co, Clin Modern Med, Moscow, Russia

[12] Gilead Sci, Foster City, CA USA

[13] Univ Klinikum Hamburg Eppendorf, Med Klin Studienambulanz Hepatol, Hamburg, Germany

[14] Univ Hosp Frankfurt, Dept Med, Frankfurt, Germany

[15] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[16] Univ Milan, CRC AM & A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

GUT | 2023年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P134

引用

页码：A103 / A104

页数：2

共 50 条

[21] Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study
Loglio, Alessandro
Ferenci, Peter
Deterding, Katja
Renteria, Sara Colonia Uceda
Sambarino, Dana
Jachs, Mathias
Schwarz, Caroline
Borghi, Marta
Port, Kerstin
Perbellini, Riccardo
Facchetti, Floriana
Degasperi, Elisabetta
Maasoumy, Benjamin
Reiberger, Thomas
Cornberg, Markus
Wedemeyer, Heiner
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 77 : S843 - S843
[22] EFFICACY OF BULEVIRTIDE AS MONOTHERAPY FOR CHRONIC HEPATITIS D (CHD): WEEK 48 RESULTS FROM AN INTEGRATED ANALYSIS
Lampertico, Pietro
Aleman, Soo
Blank, Antje
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Suri, Vithika
Manuilov, Dmitry
Ye, Lei
Flaherty, John F.
Osinusi, Anu O.
Cornberg, Markus
Brunetto, Maurizia
Wedemeyer, Heiner
HEPATOLOGY, 2022, 76 : S228 - S230
[23] Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis
Lampertico, P.
Aleman, S.
Blank, A.
Bogomolov, P.
Chulanov, V.
Mamonova, N.
Morozov, V.
Sagalova, O.
Stepanova, T.
Suri, V.
Manuilov, D.
Ye, L.
Flaherty, J. F.
Osinusi, A.
Cornberg, M.
Brunetto, M.
Wedemeyer, H.
DIGESTIVE AND LIVER DISEASE, 2023, 55 : S73 - S73
[24] 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV coinfection
Wedemeyer, Heiner
Schoeneweis, Katrin
Bogomolov, Pavel O.
Chulanov, Vladimir
Stepanova, Tatyana
Viacheslav, Morozov
Allweiss, Lena
Dandri, Maura
Ciesek, Sandra
Dittmer, Ulf
Haefeli, Walter-Emil
Alexandrov, Alexander
Urban, Stephan
JOURNAL OF HEPATOLOGY, 2020, 73 : S52 - S53
[25] Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
Lee, Stacey
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S858 - S859
[26] Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study
Freismuth, A.
Wedemeyer, H.
Aleman, S.
Brunetto, M.
Black, A.
Andreone, P.
Bogomolov, P.
Chulanov, V.
Mamonova, N.
Geyvandova, N.
Morozov, V.
Sagalova, O.
Stepanova, T.
Manuilov, D.
Suri, V.
An, Qi
Flaherty, J. F.
Osinusi, A.
Zur Wiesch, J. Schulze
Cornberg, M.
Zeuzem, S.
Lampertico, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 52 - 53
[27] PATIENT- REPORTED OUTCOMES AMONG PATIENTS WITH CHRONIC HEPATITIS DELTA TREATED WITH BULEVIRTIDE 2 MG: A LONG-TERM ANALYSIS OF THE PHASE 3 MYR301 TRIAL AT 144 WEEKS
Buti, Maria
Wedemeyer, Heiner
Aleman, Soo
Chulanov, Vladimir
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Gish, Robert
Lloyd, Andrew
Suri, Vithika
Manuilov, Dmitry
Chee, Grace
Lau, Audrey
Osinusi, Anu
Flaherty, John
Rock, Marvin
Kim, Chong Hoon
Pandey, Shubhram
Singh, Barinder
Lampertico, Pietro
HEPATOLOGY, 2024, 80 : S150 - S151
[28] Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta
Lampertico, Pietro
Bogomolov, Pavel O.
Chulanov, Vladimir
Stepanova, Tatiana
Morozov, Viacheslav
Allweiss, Lena
Dandri, Maura
Burhenne, Juergen
Blank, Antje
Ciesek, Sandra
Elsner, Carina
Dittmer, Ulf
An, Qi
Manuilov, Dmitry
Da, Ben L.
Flaherty, John F.
Urban, Stephan
Wedemeyer, Heiner
LIVER INTERNATIONAL, 2025, 45 (02)
[29] Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis
Paglia, Margaret
Peterson, Janet
Fisher, Alan C.
Qin, Zhihai
Nicholson, Susan C.
Kahn, James B.
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1433 - 1441
[30] Safety profile of 48 weeks of adefovir dipivoxil 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two Phase III studies
Heathcote, EJ
Chang, TT
Lim, SG
Hadziyannis, S
Tassopoulos, N
Tong, M
Sievert, W
Wollman, M
Van Doren, S
Fry, J
Brosgart, C
ANTIVIRAL THERAPY, 2002, 7 (04) : L105 - L106

← 1 2 3 4 5 →